Teleflex’s (TFX) Neutral Rating Reiterated at Piper Sandler

Teleflex (NYSE:TFX)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Piper Sandler in a research report issued on Friday,Benzinga reports. They presently have a $140.00 price target on the medical technology company’s stock, down from their previous price target of $255.00. Piper Sandler’s target price would suggest a potential upside of 0.73% from the company’s previous close.

TFX has been the subject of several other reports. StockNews.com raised Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Truist Financial lowered their price objective on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Mizuho reduced their target price on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Finally, Citizens Jmp cut shares of Teleflex from an “outperform” rating to a “market perform” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $225.00.

Teleflex Stock Down 21.8 %

TFX opened at $138.99 on Friday. Teleflex has a fifty-two week low of $135.95 and a fifty-two week high of $249.90. The firm has a market capitalization of $6.46 billion, a P/E ratio of 27.63, a PEG ratio of 1.73 and a beta of 1.16. The company’s 50-day moving average is $176.35 and its 200 day moving average is $205.70. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, topping analysts’ consensus estimates of $3.86 by $0.03. The firm had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. Research analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently made changes to their positions in TFX. Headlands Technologies LLC purchased a new stake in Teleflex in the fourth quarter valued at approximately $29,000. Avior Wealth Management LLC grew its holdings in Teleflex by 190.6% in the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock worth $38,000 after acquiring an additional 101 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Teleflex in the third quarter valued at about $40,000. True Wealth Design LLC raised its stake in shares of Teleflex by 16,600.0% during the third quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock valued at $41,000 after acquiring an additional 166 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in shares of Teleflex in the third quarter worth about $54,000. 95.62% of the stock is currently owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.